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INTRODUCTION
Due to the process of allelic exclusion, the development of T cells is skewed to the CD8 1 lineage in most class I major histocompatibility complex (MHC-I)-restricted T-cell receptor (TCR)-transgenic mouse lines, leading to the accumulation of single-positive CD8
1 lymphocytes in the thymus and periphery. [1] [2] [3] [4] However, exceptions have been reported in MHC-I-restricted alloantigen- 5 and autoantigen-specific 6, 7 TCRtransgenic mice, in which there was no differentiation bias for CD8 1 T cells. In these transgenic mice, most of the CD4 1 T cells expressed an MHC-I-restricted transgenic TCR, which could be detected by specific anti-TCR antibodies, and an additional rearranged endogenous MHC-II-restricted TCR through which the CD4 1 T cells could be positively selected to maintain a normal ratio of CD4 1 to CD8 1 T cells. Moreover, it was found that the CD4 1 T cells could be activated through the transgenic TCR or the endogenous TCR by antigen-expressing cells in an MHC-I-restricted alloantigen-specific TCR-transgenic mouse. 5 CD8 is critical for T-cell recognition of the MHC-I/peptide complex. By binding to MHC-I molecules on antigen-presenting cells, CD8 can strengthen MHC-I-restricted TCR signaling. 8, 9 Although it was discovered by antibody staining in several MHC-I-restricted TCRtransgenic mice that the CD4 1 T cells expressed MHC-I-restricted transgenic TCRs, 5, 6, 7 so far, there has not been direct proof to determine whether the MHC-I-restricted transgenic TCRs on the CD4 1 T cells bind to the MHC-I/peptide complex.
P1A was the first unmutated tumor antigen identified in mice, which is expressed at high levels in mouse tumor cell lines (such as mastocytoma P815 and plasmacytoma J558) and in immunologically privileged tissues (placenta and testis) and at a low but significant level in normal tissues including hematopoietic tissues. [10] [11] [12] An H-2L drestricted dominant epitope was identified as P1A [35] [36] [37] [38] [39] [40] [41] [42] [43] nonapeptide (LPYLGWLVF). 13 Although P1A is expressed at low levels in normal tissues, including lymphoid tissues, the P1A-specific TCR (Va8.3/ Vb1)-transgenic CD8 1 T cells develop normally in P1A tumor antigen-specific TCR (P1ATCR)-transgenic mice and remain highly responsive to the P1A antigen. 12 Most of CD4 1 T cells also express the MHC-I-restricted transgenic TCR, but the L d /P1A tetramer could only stain the transgenic CD8 1 T cells, not CD4 1 T cells. 7 In our study, more than a half of the CD4 1 T cells from P1ATCR-transgenic DBA/2 mice could be stained by an L d /P1A dimer when the amount of dimer for staining was increased to three-to fourfold of the usual dose. Moreover, the P1A peptide could stimulate the CD4 1 T cells to show both helper and cytotoxic functions.
MATERIALS AND METHODS

Mice and cell lines
Transgenic mice expressing a TCR specific for the H-2L d -restricted P1A tumor antigen peptide (P1A [35] [36] [37] [38] [39] [40] [41] [42] [43] : LPYLGWLVF) in the BALB/c background have been described previously 12 and backcrossed with the DBA/2 background for more than 10 generations. Heterozygous male transgenic mice were crossed with female DBA/2 mice (Vitalriver Experimental Animal Company, Beijing, China) for breeding. The offspring were genotyped by flow cytometry analysis of the expression of the transgenic TCR Va8.3 chain on CD8 1 T cells in peripheral blood mononuclear cells. All of the mice were maintained under specific pathogen-free conditions in the animal facility at the Institute of Biophysics, Chinese Academy of Sciences. All studies involving animals were approved by the Institutional Laboratory Animal Care and Use Committee.
The P815 mastocytoma cell line and the CT26 colon tumor cell line were maintained in complete medium of RPMI 1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Thermo Fisher, Beijing, China), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 U/ml penicillin G and 100 mg/ml streptomycin sulfate. 1 T cells were sorted by making two gates far away from each other to exclude contamination. Total RNA was extracted with TRI reagent (Applied Biosystems, Foster City, CA, USA) and reverse transcribed into cDNA with reverse transcriptase and an oligo-dT primer (Transgene, Beijing, China). To quantitate the cDNA, threefold serial dilutions of the cDNA reactions were subjected to PCR using primers specific for the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase for 35 cycles of 94 uC for 1 min, 55 uC for 1 min, and 72 uC for 1 min on a Peltier Thermal Cycler (MJ Research, Waltham, MA, USA). Similar amounts of cDNA were then subjected to PCR using a conserved Ca-or Cb-specific primer paired with a Va family-specific primer or Vb1-specific primer for 35 cycles of 94 uC for 1 min, 55 uC for 1min and 72 uC for 1 min. The primers were chosen according to a previous report.
Flow cytometry analysis
14 PCR reaction products were electrophoresed on 1.2% agarose gels.
In vitro T-cell activation and cytotoxicity assays Pooled lymph node and spleen cells were depleted of CD8 1 or CD4 1 cells using magnetic beads according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany) and then labeled with 5 mM carboxyfluorescein succinimidyl ester (CFSE) and stimulated with P1A 35-43 peptide at different concentrations for 1-3 days. Cytokines in the culture supernatant were detected using the Cytometric Bead Array Mouse Th1/Th2
Cytokine Kit or Inflammation Kit (BD Biosciences) according to the manufacturer's instructions. Two days after stimulation, the stimulated cells were treated with Brefeldin A for 5 h for interferon (IFN)-c intracellular staining according to the manufacturer's instructions (eBioscience).
The CD4 1 -or CD8 1 -depleted spleen and lymph node cells were activated with P1A 35-43 peptide-pulsed isolated dendritic cells for 3 days and purified by Ficoll. P815 (P1A 1 and H-2L d1 ) tumor cells stained with a 5 mM CFSE solution were used as specific target cells, and CT26 (P1A 2 and H-2L d1 ) tumor cells stained with a 0.5 mM CFSE solution (CFSE low ) were used as nonspecific target cells. A mixture of P815 and CT26 tumor cells at a 1 : 1 ratio was incubated with activated CD8 1 or CD4 1 T cells at different E/T ratios in a round-bottom 96-well plate for 16 h. The cells were harvested and stained with 7-aminoactinomycin D (7-ADD). The CFSE profiles were analyzed using the 7-AAD 2 CFSE 1 gate. Cytotoxicity was determined by the following formula: 1-Ratio (P815/CT26) 1effector / Ratio (P815/CT26) 2effector . The results are representative of three independent experiments.
Alloresponse
Lymph node cells from P1ATCR-transgenic and non-transgenic DBA/ 2 mice were labeled with 5 mM CFSE and cocultured with irradiated CD11c 1 cells isolated from the splenocytes of C57BL/6 mice by magnetic-activated cell sorting at different ratios for 5 days. The proliferation of CD4
1 T cells as monitored by CFSE dilution.
RESULTS
CD4
1 T cells expressing an MHC-I-restricted transgenic T-cell receptor (TgTCR) bind to the MHC-I/peptide complex It has been reported that the CD4 1 T cells from P1ATCR-transgenic mice cannot be stained by the L d /P1A tetramer, even most of these cells express the TgTCR. 5 In our study, we found that approximately 90% of To determine whether the dimer-negative CD4 1 T cells in P1ATCR-transgenic mice express the P1ATCR transgenes, we used RT-PCR to detect the expression levels of the transgenic TCR Va8 and Vb1 chains in dimer-positive and dimer-negative CD4 1 T cells. As shown in Figure 1c , the Vb1 chain was expressed at similar levels in dimerpositive and dimer-negative CD4 1 T cells, but dimer-positive CD4 (filled, black) . The results are representative of at least three independent experiments. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IgG, immunoglobulin G; mAb, monoclonal antibody; MHC, major histocompatibility complex; P1ATCR, P1A tumor antigen-specific T-cell receptor; TgTCR, transgenic T-cell receptor; TCR, T-cell receptor. Figure 3a , both the non-CD8
CD4 1 T cells expressing an MHC-I-restricted TCR
1 and non-CD4 1 populations of the lymph node and spleen cells could be stimulated with P1A peptide to secrete IFN-c, TNF-a, IL-2 and IL-6. However, the cytokine production of the CD4 1 T cells was much lower than that of CD8 1 T cells. The production of IFN-c by CD4
1 T cells was confirmed by intracellular staining (Figure 3b ). In addition, the activated CD4 1 T cells also produced Th2 cytokines including IL-4, IL-5 and IL-10, which could hardly be detected in non-CD4 1 cells. Last, we checked whether this population of activated CD4
1 T cells had cytotoxic activity against tumor cells expressing P1A antigen. We performed an in vitro killing assay using a mixture of P815 (H-2 d , P1A
1 and CFSE hi ) and CT26 (H-2 d , P1A 2 and CFSE low ) tumor cells as targets. As shown in Figure 3c , the CD4 1 T cells activated with P1A peptide were able to kill P815 tumor cells, although the activity was much lower than that of activated CD8 1 T cells. Because P815 tumor cells do not express MHC-II molecules, 15 the killing activity of CD4 1 T cells in the transgenic mice expressed the TCR Va8.3 chain, they expressed the Va2 chain in a comparable frequency to that in non-transgenic mice (Figure 4c) . Thus, the transgenic CD4 1 T cells co-expressed an MHC-I-restricted TgTCR as well as a rearranged endogenous TCR, and the latter might permit positive selection of CD4 1 T cells on MHC-II products. To test the function of the endogenous TCR, we used an alloresponse assay to compare the polyclonal response of transgenic CD4
1 T cells to alloantigen with that of normal CD4 1 T cells. Lymph node cells from P1ATCR-transgenic DBA/2 mice and littermates were labeled by CFSE and cocultured with irradiated isolated CD11c 1 cells from C57BL/6 mice. As shown in Figure 5 , the transgenic CD4 1 T cells 1 T cells with the L d /P1A tetramer. 7 In our studies, we also found that few CD4 1 T cells were weakly positive for L d /P1A dimer staining using a normal dose at which most CD8
1 T cells were strongly positive. However, when a quadruple dose of dimer was used, more than 50% of the CD4 1 T cells also showed specific cytotoxic activity to P815 tumor cells. Compared to those of CD8 1 T cells, the CD4 1 T cell responses were much lower, which was reflected by the need for a higher concentration of peptide for stimulation. This need for a higher peptide concentration may result from a weaker interaction between the TCR and the MHC-I/peptide complex without CD8 
